![]() |
Name |
Asperphenalenone E
|
Molecular Formula | C35H46O9 | |
IUPAC Name* |
(2S)-2-[(2E,6E,10Z,14R)-14,15-dihydroxy-11-(hydroxymethyl)-3,7,15-trimethylhexadeca-2,6,10-trienyl]-2,4,6,9-tetrahydroxy-5,7-dimethylphenalene-1,3-dione
|
|
SMILES |
CC1=CC(=C2C3=C1C(=C(C(=C3C(=O)[C@@](C2=O)(C/C=C(\C)/CC/C=C(\C)/CC/C=C(/CC[C@H](C(C)(C)O)O)\CO)O)O)C)O)O
|
|
InChI |
InChI=1S/C35H46O9/c1-19(11-8-12-23(18-36)13-14-25(38)34(5,6)43)9-7-10-20(2)15-16-35(44)32(41)27-24(37)17-21(3)26-28(27)29(33(35)42)31(40)22(4)30(26)39/h9,12,15,17,25,36-40,43-44H,7-8,10-11,13-14,16,18H2,1-6H3/b19-9+,20-15+,23-12-/t25-,35+/m1/s1
|
|
InChIKey |
YKKQCMZRKKBHMY-KVHDNOMISA-N
|
|
Synonyms |
Asperphenalenone E; CHEMBL4164759; ZINC67902705; (2S)-2-[(2E,6E,10Z,14R)-14,15-dihydroxy-11-(hydroxymethyl)-3,7,15-trimethyl-hexadeca-2,6,10-trienyl]-2,4,6,9-tetrahydroxy-5,7-dimethyl-phenalene-1,3-dione
|
|
CAS | NA | |
PubChem CID | 95223066 | |
ChEMBL ID | CHEMBL4164759 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 610.7 | ALogp: | 6.7 |
HBD: | 7 | HBA: | 9 |
Rotatable Bonds: | 13 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 176.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 44 | QED Weighted: | 0.112 |
Caco-2 Permeability: | -5.128 | MDCK Permeability: | 0.00000563 |
Pgp-inhibitor: | 0.567 | Pgp-substrate: | 0.999 |
Human Intestinal Absorption (HIA): | 0.891 | 20% Bioavailability (F20%): | 0.3 |
30% Bioavailability (F30%): | 0.066 |
Blood-Brain-Barrier Penetration (BBB): | 0.007 | Plasma Protein Binding (PPB): | 94.06% |
Volume Distribution (VD): | 0.646 | Fu: | 1.40% |
CYP1A2-inhibitor: | 0.247 | CYP1A2-substrate: | 0.125 |
CYP2C19-inhibitor: | 0.083 | CYP2C19-substrate: | 0.087 |
CYP2C9-inhibitor: | 0.564 | CYP2C9-substrate: | 0.602 |
CYP2D6-inhibitor: | 0.601 | CYP2D6-substrate: | 0.144 |
CYP3A4-inhibitor: | 0.372 | CYP3A4-substrate: | 0.21 |
Clearance (CL): | 1.415 | Half-life (T1/2): | 0.441 |
hERG Blockers: | 0.009 | Human Hepatotoxicity (H-HT): | 0.112 |
Drug-inuced Liver Injury (DILI): | 0.345 | AMES Toxicity: | 0.289 |
Rat Oral Acute Toxicity: | 0.025 | Maximum Recommended Daily Dose: | 0.969 |
Skin Sensitization: | 0.865 | Carcinogencity: | 0.06 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.065 |
Respiratory Toxicity: | 0.582 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003496 | ![]() |
0.858 | D05XQE | ![]() |
0.341 | ||
ENC003842 | ![]() |
0.858 | D03VFL | ![]() |
0.283 | ||
ENC003494 | ![]() |
0.797 | D09XWD | ![]() |
0.282 | ||
ENC005339 | ![]() |
0.671 | D0WY9N | ![]() |
0.258 | ||
ENC005340 | ![]() |
0.655 | D00FSV | ![]() |
0.224 | ||
ENC005338 | ![]() |
0.645 | D0G4OD | ![]() |
0.220 | ||
ENC005341 | ![]() |
0.644 | D0FX2Q | ![]() |
0.220 | ||
ENC005337 | ![]() |
0.623 | D08FPM | ![]() |
0.212 | ||
ENC003495 | ![]() |
0.599 | D01ZUA | ![]() |
0.208 | ||
ENC004068 | ![]() |
0.471 | D04VEJ | ![]() |
0.208 |